Breaking News


Twice-daily versus once-daily topical pimecrolimus cream for relapse prevention in pediatric atopic dermatitis


A multicenter, randomized, double-blind trial enrolled 300 patients aged 2-17 years with mild-severe atopic dermatitis (AD) for treatment with once or twice daily pimecrolimus cream 1% for up to 16 weeks. The patients had been initially treated for up to 6 weeks with b.i.d. topical pimecrolimus cream until clearance. Those achieving a decrease of 1 point or more on the Investigator's Global Assessment (IGA) scale were then randomized to double-blind treatment with b.i.d. or q.d. pimecrolimus. Pimecrolimus was discontinued during disease remission (when IGA = 0). The primary endpoint of the double-blind phase was disease relapse (worsening requiring topical corticosteroids or additional/alternative therapy and confirmed by IGA score of 3 or more ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list